



Handwritten notes:
Definieren von AIDS
Definition - 1981

ACQUIRED IMMUNE DEFICIENCY SYNDROME EMERGENCIES

Handwritten notes:
Acquired Immune Deficiency

Report of a WHO Meeting
Geneva, 22-25 November 1983

The issue of this document does not constitute formal publication. It should not be reviewed, abstracted or quoted without the agreement of the World Health Organization. Authors alone are responsible for views expressed in signed articles.

Ce document ne constitue pas une publication. Il ne doit faire l'objet d'aucun compte rendu ou résumé ni d'aucune citation sans l'autorisation de l'Organisation mondiale de la Santé. Les opinions exprimées dans les articles signés n'engagent que leurs auteurs.

CONTENTS

	<u>Page</u>
List of Participants	3
I. Introduction	6
II. Epidemiology and Surveillance	6
A. North America	6
1. United States of America	6
2. Canada	7
B. Europe	7
C. The Caribbean	7
D. Central Africa	7
E. AIDS in other areas of the World	8
III. Clinical Diagnosis and Management	8
A. General Considerations	8
B. Clinical Features and Management	8
1. Opportunistic Infections	8
2. Malignancies	9
3. Other Clinical Aspects	9
4. Immunologic Features	9
5. Treatment	10
6. Clinical Presentations in Tropical Countries	10
C. AIDS-related Symptom Complex	10
IV. Etiology	10
V. Prevention and Control	11
A. General Considerations	11
B. Education of the Public	11
C. Health Care Workers and Allied Professionals	12
D. Blood and Blood Products	12
VI. Conclusions and Recommendations	13
Appendix 1	16
Appendix 2	17
Figure 1	20
Table 1	21
Table 2	22
Table 3	23

List of Participants

Members

- Dr N. Achour, Directeur de l'Evaluation des Soins de Santé de Base, Ministère de la Santé Publique, Tunis, Tunisia
- Dr M. Al Moufarreh, Chief Internist, Riyadh Central Hospital, Riyadh, Saudi Arabia
- Dr C. Blanchard, Internist and Chairman, Department of Medicine, Faculty of Medicine, University of Haiti, Port-au-Prince, Haiti
- Dr F. Bouges, Head, Medical Department, King Fahd Hospital, Jeddah, Saudi Arabia
- Dr A. Chernoff, Director, Division of Blood Diseases and Resources, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States of America
- Dr A.J. Clayton, Director General, Health Protection Branch, Laboratory for Disease Control, Ottawa, Ontario, Canada
- Dr M.A. Conant, Co-Director, Kaposi's Sarcoma Foundation, San Francisco, California, United States of America
- Dr R.A. Coutinho, Department of Infectious Diseases, The Municipal Health Service of Amsterdam, Netherlands (Rapporteur)
- Dr J.W. Curran, Director, AIDS Activity, Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia, United States of America
- Dr W. Dowdle, Director, Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia, United States of America (Chairman)
- Dr P. Ebbesen, Director, Institute of Cancer Research, Aarhus, Denmark
- Professor V.P. Eijssvoogel, Director of Research, Central Laboratory, Netherlands Red Cross Blood Transfusion Service, Amsterdam, Netherlands
- Dr J.L. Fahey, Department of Medical Microbiology and Immunology, UCLA School of Medicine, Los Angeles, California, United States of America
- Dr D.P. Francis, Host Factors Division, Centers for Disease Control, Atlanta, Georgia, United States of America
- Dr M. Garnier, Secretary of State, Department of Public Health and Population, Port-au-Prince, Haiti
- Dr I.D. Gust, Virus Laboratory, Fairfield Hospital, Fairfield, Australia
- Dr M.R. Hilleman, Senior Vice President, Merck Sharp & Dohme Research Laboratories, Division of Merck & Co. Inc., West Point, Pennsylvania, United States of America
- Dr B. Kapita, Médecine Interne, Hôpital Mama Yemo, Kinshasa, Zaire
- Dr R.M. Khaitov, Deputy Director, Institute of Immunology, Ministry of Health of the USSR, Moscow, USSR
- Professor M.A. Koch, Robert Koch-Institut des Bundesgesundheitsamt, Berlin, Federal Republic of Germany
- Professor A. Lafontaine, Director, Institut d'Hygiène et d'Epidémiologie, Brussels, Belgium

Dr J. Leibowitch, Immunologie, Hôpital Raymond Poincaré, Université René Descartes, Garches, France

Dr J. Leikola, Director, Blood Transfusion Service, League of Red Cross Societies, Geneva, Switzerland

Dr P. Mazebo, Chef, Service de Dermatologie, Cliniques Universitaires, Kinshasa, Zaïre

Dr D. McClelland, Blood Transfusion Service, Royal Infirmary, Edinburgh, Scotland

Dr L. Montagner, Chef de l'Unité d'Oncologie Virale, Institut Pasteur, Paris, France

Professor K. Okochi, Clinical Laboratory, Kyushu University Hospital, Fukuoka, Japan

Dr D. Pal, Adviser (STD) to the Government of India, Ministry of Health and Family Welfare, New Delhi, India

Dr G. Papaevangelou, Professor of Epidemiology and Medical Statistics, Athens School of Hygiene, Athens, Greece

Dr R. Penny, Associate Professor of Medicine, Department of Immunology, St. Vincent's Hospital, Darlinghurst, Australia

Dr J. Petricciani, Director, Office of Biologics, National Center for Drugs and Biologics, Bethesda, Maryland, United States of America

Dr G. Pierre, Internist and Cardiologist, Department of Physiology, Faculty of Medicine, University of Haiti, Port-au-Prince, Haiti

Professor M. Seligmann, Laboratoire d'Immunologie, Hôpital Saint-Louis, Paris, France

Dr S. Sostroamidjojo, Chief, Directorate of Diseases CDC, Ministry of Health, Jakarta, Indonesia

Dr A. Traisupha, Director, Division of Venereal Diseases, Department of Communicable Disease Control, Ministry of Public Health, Bangkok, Thailand

Dr J.G. Watt, Protein Fractionation Centre, Edinburgh, Scotland

Dr J. Wells*, Immunologist, The Kolling Institute, Royal North Shore Hospital, Sydney, Australia

Dr H. Zoffmann, Head, Department of Epidemiology, Statens Serum Institut, Copenhagen, Denmark

Professor A.J. Zuckerman, London School of Hygiene and Tropical Medicine, London, United Kingdom

Secretariat

Dr G.M. Antal, Medical Officer, Bacterial and Venereal Infections, Division of Communicable Diseases, WHO, Geneva, Switzerland

Dr F.A. Assaad, Director, Division of Communicable Diseases, WHO, Geneva, Switzerland

Dr T. Bektimirov, Chief Medical Officer, Virus Diseases, Division of Communicable Diseases, WHO, Geneva, Switzerland

* Unable to attend

- Dr G.Y. Causse, Chief Medical Officer, Bacterial and Venereal Infections, Division of Communicable Diseases, WHO, Geneva, Switzerland (Secretary)
- Dr L. Houang, Chief Medical Officer, Health Laboratory Technology, Division of Diagnostic, Therapeutic and Rehabilitative Technology, WHO, Geneva, Switzerland
- Dr T. Kereselidze, Medical Officer, Bacterial and Venereal Infections, Division of Communicable Diseases, WHO, Geneva, Switzerland
- Mr V.R. Oviatt, Chief, Special Programme on Safety Measures in Microbiology, Division of Communicable Diseases, WHO, Geneva, Switzerland
- Dr F.T. Perkins, Chief Medical Officer, Biologicals, Division of Diagnostic, Therapeutic and Rehabilitative Technology, WHO, Geneva, Switzerland
- Dr A. Romero*, Regional Adviser in Epidemiological Surveillance, WHO Regional Office for the Americas, Washington, D.C., United States of America
- Dr G. Torrigiani, Chief Medical Officer, Immunology, Division of Noncommunicable Diseases, WHO, Geneva, Switzerland
- Dr B. Velimirovic, Regional Adviser for Communicable Diseases, WHO Regional Office for Europe, Copenhagen, Denmark

* Unable to attend

I. INTRODUCTION

The acquired immunodeficiency syndrome (AIDS), a clinical entity that includes fatal opportunistic infections and otherwise rare malignancies, was first reported in the United States in 1981. In retrospect, the first cases had occurred in that country as early as 1978. Soon after these first reports in 1981 similar cases began to be reported from other areas of the world. As in the United States, retrospective studies indicated that AIDS in central Africa and the Caribbean region may also have occurred as early as the late 1970s. In some of these areas, such as in most Western European countries and Canada, the epidemiologic pattern is very similar to the pattern in the United States, with the majority of cases in homosexual men. In other areas, such as central Africa and the Caribbean the pattern seems to be different, with no particular risk factors having been identified for the majority of cases.

A consultative meeting was convened by the World Health Organization to assess the present AIDS situation in the world and to encourage collaboration between the different nations affected by this disease. This memorandum reviews current information on AIDS and gives conclusions and recommendations concerning epidemiology and surveillance, etiology, clinical diagnosis and management, and prevention and control.

II. EPIDEMIOLOGY AND SURVEILLANCE

The epidemiologic pattern of AIDS differs according to geographic area and is therefore described separately for each area.

A. North America

1. United States of America

There is no specific diagnostic test for AIDS. For surveillance purposes in 1981 the Centers for Disease Control (CDC) adopted criteria for defining AIDS. These criteria included reliably diagnosed marker conditions considered indicative of severe underlying immunodeficiency with no identifiable cause (Appendix I). This definition has been useful for monitoring trends and detecting disease patterns, but it may underestimate the extent of the problem. Clinicians have recognized that a variety of chronic but nonspecific symptoms and physical findings also may be related to the syndrome.

AIDS is a notifiable condition in most States and diagnosed cases have increased considerably since 1981 (Figure 1). However, retrospective studies have revealed a small number of cases diagnosed as early as 1978. Cases diagnosed in 1983 are underestimated in Figure 1 because of the lag between date of diagnosis and date of report for many cases. Nearly 75 percent of all the cases have been reported in the past 12 months. Over 40 percent of the cases are known to have been fatal. Fewer than 20 percent of patients have survived 2 years after AIDS was diagnosed.

Over 70 percent of reported cases in the United States have been in homosexual or bisexual men (Table 1). The 326 patients listed as "other" include 26 (1%) reported to be sexual contacts of persons in populations with an increased incidence of AIDS, 19 (0.7%) with hemophilia with no other known risk factor, 33 (1%) who had received transfusions within 5 years before diagnosis, 131 (4.8%) persons born in Haiti and recent immigrants who were not identified as being in a risk group, and 12 (0.4%) with Kaposi's Sarcoma (KS) and a normal immunologic status. It is likely that most of these KS patients represent "background" cases of classic KS rather than AIDS. Of the remaining 105 (3.6%), more than half had died before an adequate risk-factor history could be obtained.

AIDS has primarily affected young adults; 90 percent of the patients have been in the 20-to-49-year age group. Although cases have been reported from 42 of 50 States, the syndrome appears until now to be concentrated in five urban areas (Table 2).

Additionally, 35 cases of "pediatric AIDS" have been reported to CDC. Although the difficulty in ruling out other causes of immunodeficiency in infants has made the acceptance of this condition controversial, reported cases are increasing. Approximately two-thirds of pediatric patients were born into families of persons in AIDS high-risk groups and more than half of the remaining third have a history of having received transfusions.

2. Canada

As of November 15, 1983, 50 cases had been reported from Canada; 22 (44%) of these had been reported from Montreal. The epidemiologic pattern is similar to that of the United States.

B. Europe

AIDS has been increasingly reported in many countries in Europe (Table 3). Among citizens of European countries, the risk factors and demographic characteristics resemble generally cases reported in the United States, with over 70 percent of cases occurring in homosexual men. Fewer than 2 percent of cases have occurred in heterosexual abusers of intravenous drugs and 4 percent in persons with hemophilia.

It is noteworthy that 59 (22%) of 268 cases reported in Europe have been reported among persons born in Africa (including Zaire, Congo, Mali, Gabon, Rwanda, Burundi, Chad, and Cameroon). Thirty-seven percent of the African patients were women. No specific risk factors could be identified for the majority of these 59 patients.

C. The Caribbean

In retrospect, sporadic cases of AIDS were diagnosed in young adults in Haiti as early as 1979, however, most of the November 1983 total of 202 cases have been reported since the beginning of 1982. Eighty-two percent of the patients were in the 20-to-40-year age group, 85 percent were men, and over 80 percent were from the Port-au-Prince metropolitan area. In a special study of a subgroup of these patients, potential risk factors (bisexual activity, receipt of blood transfusions) were identified for 12 percent of the men and 22 percent of the women with AIDS. All educational and socioeconomic levels have been affected.

In addition to risk factors previously recognized, the role of other possible factors such as heterosexual transmission are being examined. Injections using non-sterilized needles unassociated with drug abuse are of potential importance. There has been no evidence of spread through water, air, food, or ordinary social contact.

D. Central Africa

Because of recent reports documenting an increase in cryptococcal meningitis in Zaire and because Zairian patients with AIDS have been recently reported in Europe, a special study on AIDS was recently undertaken in Kinshasa. The clinical criteria for suspected AIDS cases included one or more of the following: diarrhea of at least 2 months' duration with weight loss of 10 percent or more of body weight, unexplained recurrent fever, pneumonia of unknown etiology refractory to standard therapy, cryptococcal meningitis, Kaposi's sarcoma, and presence of other serious opportunistic infections (e.g., oroesophageal candidiasis). T-cell subsets were determined on persons clinically suspected of having AIDS and demonstrating skin test anergy with either multiple antigens or tuberculin. Persons meeting the clinical criteria, having skin test anergy and having an absolute number of T-helper cells of ≤ 400 and a T-helper/suppressor ratio of ≤ 0.6 were regarded as having AIDS.

In October and November 1983, 49 cases of AIDS were diagnosed in two large hospitals in Kinshasa. Forty-one percent of the cases were in women. No definite risk factors have been identified. The mean ages of male and female AIDS patients were 42 and 30 years, respectively. Twenty-one percent of the men and 90 percent of the women were unmarried. All social and economic groups and geographic regions were represented; over 80 percent of the AIDS patients were residents of Kinshasa.

E. AIDS in Other Areas of the World

Besides the cases in the United States, Canada, and Haiti, 44 cases of AIDS in the Americas had been reported to the Pan American Health Organization as of September 12, 1983. Of these 44 cases, 22 were reported from Brazil, 12 from Argentina, 4 from Mexico, 2 from Jamaica, 2 from Uruguay, 1 from Surinam, and 1 from Trinidad and Tobago.

Five AIDS cases in homosexual men have been reported from Australia. Two suspected cases have been reported from Japan.

III. CLINICAL DIAGNOSIS AND MANAGEMENT

A. General Considerations

AIDS results from cellular immune deficiency and is manifested by opportunistic infections and/or selected malignancies. Clinical diagnosis of fully expressed AIDS would ordinarily satisfy the following criteria: 1) A reliable diagnosis of opportunistic infection and/or malignancy (Appendix 1). The latter includes Kaposi's sarcoma, B cell lymphoma, and possibly other tumors. 2) Evidence of cellular immune deficiency. Characteristically, AIDS patients show skin test anergy, persistent reduction of T-helper cells, decreased ratio of T-helper to T-suppressor cells, impaired proliferative response to mitogens and antigens, reduced cellular cytotoxicity, and increased serum immunoglobulins. 3) No known cause of cellular immune deficiency, such as primary immunodeficiency syndromes, corticosteroid therapy, chemotherapy or radiotherapy, or pre-existing diseases such as malignancies or severe protein-caloric malnutrition.

Since the symptoms, clinical and immunological, alone are not specific for AIDS, a careful history concentrating upon epidemiologic risk factors may be helpful in differential diagnosis and management.

B. Clinical Features and Management

1. Opportunistic Infections

A striking feature of the AIDS syndrome is the wide spectrum and frequency of infections (Appendix 1). The organisms causing the infection are life-threatening pathogens seldom seen as such in normal hosts. Disease in AIDS patients may begin with insidious signs and symptoms, and the process may be more diffuse than when the same conditions are seen in other immunocompromised patients. These findings are consistent with a limited immune response by the patient and inability to contain the infection.

Four patterns of disease occur in AIDS patients. The "pulmonary pattern" consists of dyspnea, hypoxemia, chest pain, and diffuse pulmonary infiltrates on chest x-ray. The most prevalent fatal infection in North America and Europe has been Pneumocystis carinii pneumonia, and there is a high recurrence rate after stopping therapy. In addition to Pneumocystis carinii, Legionella pneumophila and cytomegalovirus (CMV) infections produce a similar pulmonary picture.

The "central nervous system pattern" is seen in about 30 percent of AIDS cases and occurs in four major forms: 1) infections including Toxoplasma gondii abscesses, cryptococcal meningitis, progressive multifocal leukoencephalopathy, Mycobacterium avium intracellulare (MAC), and subacute encephalitis possibly attributable to cytomegalovirus infection; 2) tumors such as cerebral lymphoma; 3) vascular complications including non-bacterial thrombotic endocarditis and cerebral hemorrhage associated with thrombocytopenia; 4) central nervous system problems with focal brain lesions and self-limiting aseptic meningitis.

The "gastrointestinal pattern" with diarrhea and weight loss in cases has been associated with enteric infections with cryptosporidium and other organisms. In many cases the cause of weight loss and diarrhea remains unclear.

The pattern of "fever of unknown origin" with weight loss, malaise, and weakness is also seen. Mycobacterium avium intracellulare infections have been demonstrated in bone marrow, lymph nodes, or liver biopsy specimens from some of these individuals.

Most patients who recover from a given infection develop subsequent opportunistic infections either as a relapse or as a result of infection with a new agent. Many patients continue to have a wasting syndrome and experience infections such as oral thrush.

2. Malignancies

Over 30 percent of the patients with AIDS described in North America and Europe have Kaposi's sarcoma (KS). The disease is histologically indistinguishable from classical KS both in the United States and Africa. However, a number of clinical features differ. For example, while traditional KS is usually limited to the extremities, KS in AIDS is often generalized, with lymph node, mucous membrane, and visceral involvement. Patients with traditional KS usually have an indolent course and respond to radiation or chemotherapy; KS in patients with AIDS is more aggressive and the response to chemotherapy has been variable. However, many clinicians have avoided using chemotherapy to avoid further compromising the patients' immunologic status. Patients with KS-AIDS often have life-threatening opportunistic infections.

An excess incidence of tumors especially in the central nervous system, and undifferentiated non-Hodgkin's lymphoma has been observed in populations with a higher incidence of AIDS.

3. Other Clinical Aspects

Depression and perception of isolation are common among AIDS patients. There is often anxiety about transmitting AIDS to intimate contacts. Health care workers who display fear of patients with AIDS contribute further to the patients' feelings of depression and isolation.

4. Immunologic Features

Skin-test anergy is common in patients with AIDS, and much evidence indicates that the immunopathology of AIDS is largely within the cellular immune system. One of the two major subpopulations of T-cells*, the T-helper cells, is characteristically reduced. Furthermore, the ratio of T-helper to T-suppressor cells is usually reduced as a consequence of the T-helper cell reductions and in some cases T-suppressor cell increases. T-cell functions, such as proliferative responses to mitogens and antigens, and cytotoxic functions are also reduced in AIDS patients. B cells are often activated as evidenced by elevated serum levels of IgG and IgA and increased B cell regions in the enlarged lymph node early in the course of the disease.

* T lymphoid cells can be divided into two major subpopulations on the basis of distinctive surface antigens recognized by monoclonal antibodies. Antigens T4 and Leu 3 are characteristic of the numerically larger subpopulation and T8 and Leu 2 of the numerically smaller subpopulation. T-helper/inducer functions are associated with the former group, and many T-suppressor/cytotoxic functions are found in the latter group. These correlations are not absolute, however. In clinical publications the T-helper and T-suppressor terms are commonly used to describe the two distinctive subsets.

5. Treatment

To date no therapy has resulted in significant improvement of the underlying cellular immune deficiency. The present treatment of AIDS involves specific therapies for infectious diseases and cancers as well as supportive care.

Trimethoprim-sulfamethoxazole (TMP-SMZ) is the drug of choice for Pneumocystis carinii pneumonia. Many patients with AIDS, however, have toxic allergic reactions to TMP-SMZ, including morbiliform eruption or profound leukopenia. Such patients with Pneumocystis carinii pneumonia or those who fail to respond to TMP-SMZ treatment are treated with pentamidine isethionate. The prognosis for AIDS patients with KS without opportunistic infections, is generally better than for other AIDS patients.

6. Clinical Presentations in Tropical Countries.

Initial observations about the clinical presentations of AIDS in Haiti and Zaire indicate some differences from AIDS in North America and Europe. Maculopapular rashes and gastrointestinal problems including severe, persistent diarrhea and oral and esophageal candidiasis have been recognized more frequently in patients from Haiti and Zaire. Localized and disseminated tuberculosis is also more common and may respond poorly to therapy. Pneumocystis carinii pneumonia and KS affect a smaller proportion of patients from Zaire and Haiti with AIDS. Toxoplasmosis of the central nervous system has been diagnosed with greater frequency among Haitians with AIDS and cryptococcal meningitis more frequently among patients from Zaire. Persistent lymphopenia, oral thrush, or cutaneous eruptions indicate the need for further evaluation of patients with unexplained symptoms. Patients should be referred to centers where further diagnosis and therapy for AIDS-associated conditions is available.

C. AIDS-related Symptom Complex

Persons in populations with an increased incidence of AIDS may exhibit one or more of the following clinical features: lymphadenopathy, fatigue/malaise/anorexia, weight loss greater than 10 percent of body weight, fever, night sweats, unremitting diarrhea, thrombocytopenia, or opportunistic infections. Laboratory evidence of cellular immune changes is found in many of these patients. Though such symptoms are often considered AIDS-related, they may represent a milder form of the illness since follow-up of selected groups of homosexual men with this symptom complex indicate that fewer than 10 percent manifest the life threatening form of AIDS within 1 year.

IV. ETIOLOGY

The etiology of AIDS is unknown, but the epidemiologic pattern is most consistent with its being caused by a transmissible agent. Transmission of the presumed agent of AIDS appears to occur by sexual contact, by blood sharing (either by therapeutic blood or blood products or by shared needles used for illicit drugs), or during the birth process (or possibly intrauterine).

Although there are other etiologic possibilities, either alone or as cofactors, the most likely cause of AIDS is a virus. Support for this is based on observations that 1) the disease distribution is similar to hepatitis B in many industrialized countries, 2) the pathophysiologic characteristics of the disease resemble those of some animal viruses (feline leukemia virus), 3) AIDS occurs in recipients of filter-sterilized blood coagulation factors, therefore the putative agent should be capable of passing through such filters, 4) epidemiologic findings are consistent with person-to-person spread, and 5) conventional identification techniques for bacteria, mycoplasma, fungi, and similar agents to AIDS have been unsuccessful to date.

The search for a candidate agent has involved many laboratories and has applied most known microbiological and biochemical techniques. Transmission experiments with laboratory animals and non-human primates are in progress.

Serologic testing of blood from AIDS patients has revealed a high prevalence of infection with cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex 1 and 2, hepatitis B virus, and hepatitis A virus. However, tests on serum samples from AIDS patients and well matched controls have provided no convincing evidence that these agents have an etiologic role.

Conventional isolation attempts have also yielded evidence of infection with herpes viruses and adenoviruses. The most common isolates have been CMV and EBV. CMV has been suggested as a candidate agent for AIDS because of its high prevalence in the populations at risk for AIDS and because CMV associated syndromes have been described as having clinical and laboratory evidence of immunosuppression, such as temporary inversion of the T-helper/T-suppressor ratio. Adenoviruses have been isolated less frequently, and isolates are of various genotypes and serotypes.

Retroviruses have been considered as candidate agents for AIDS. Certain retroviruses are capable of causing immunosuppressive and neoplastic diseases in animals after long latency periods. Since retroviruses produce chronic viremia, they could also be transmitted by blood. The best characterized human retrovirus, human T-cell leukemia virus (HTLV), has tropism for T-cells of the helper-inducer phenotype; these infected phenotypic helper cells have been shown to be functionally incompetent.

Several laboratories in various parts of the world have identified retroviruses in cultures of lymphocytes from patients with AIDS or lymphadenopathy. In addition, HTLV-related nucleic acid sequences have been detected in cultured cells from a few AIDS patients. Antibodies to membrane antigens on the surface of HTLV-infected lymphocytes and to purified virus isolates have been found in patients with AIDS. The prevalence of membrane-associated antibodies in patients with AIDS or in homosexual men with generalized lymphadenopathy has been significantly higher than in controls, though the prevalence for AIDS patients does not exceed 50 percent.

V. PREVENTION AND CONTROL

A. General Considerations

Sufficient information is available now to permit health authorities to make certain recommendations that may decrease the incidence of AIDS among the groups that are at highest risk of acquiring the syndrome. For example, epidemiologic data in North America and Europe indicate that the majority of AIDS cases occur in homosexual men and that those men with multiple sexual partners are at highest risk. These findings permit public health authorities in North America and Europe to work together with representatives of homosexual groups to formulate and distribute recommendations to lower the risk of contracting AIDS for homosexual men.

Spouses of AIDS patients have also been shown to be at an increased risk of acquiring the syndrome. Whether persons with multiple heterosexual sex partners are also at greater risk of acquiring AIDS is unknown, the low incidence in North America and Europe suggests that, if so, the risk probably is considerably less than that for homosexual men.

Although the mode of transmission in tropical countries is not clear, injections with unsterile needles and syringes may play a role since sharing of contaminated needles has been perceived as the risk factor among drug users in North America. Local health authorities can make it clear that improper sterilization of needles and syringes for medical purposes theoretically increases the risk for transmitting AIDS, as well as other infections.

B. Education of the Public

There have been many misconceptions about AIDS resulting from transmittal of inaccurate or incomplete information. National advisory boards or committees have effectively combatted these and other problems by providing factual, up-to-date information to the communications media and by making recommendations to specific groups.

C. Health-Care Workers and Allied Professionals

There has been no firm evidence of occupationally related transmission of AIDS to health-care workers, although more than 3,000 patients have been cared for in hospitals and clinics throughout the world. Of the more than 2,600 AIDS patients in the United States, 4 were reported to be health-care personnel not known to belong to groups at increased risk for AIDS. None of these 4 patients had had any direct known exposure to AIDS patients in their course of duty. Despite these findings, caution should be exercised by those involved in direct patient care or in work with clinical or laboratory specimens.

In industrialized countries the epidemiologic pattern of AIDS resembles the disease distribution and mode of spread of hepatitis B virus. Therefore, the precautions when taking care of AIDS patients and when handling specimens obtained from them should be similar to the recommended precautions with hepatitis B patients, whose blood and body fluids likely to have been contaminated with blood are considered infective. The current concern with AIDS serves as a reminder that laboratory workers must always employ great care when handling blood and tissue specimens.

In the United States, the Centers for Disease Control have issued guidelines for clinical and laboratory staff, dental-care personnel, persons performing necropsies or providing mortician services and persons handling or taking care of experimental animals inoculated with potentially infectious materials (Appendix 2).

D. Blood and Blood Products

AIDS cases have occurred both in hemophiliacs receiving clotting factor concentrates and in recipients of blood and blood component transfusions who do not have other known risk factors. Approaches to reducing the possibility of spreading AIDS by blood and blood products include 1) educating the general public and donor groups, 2) excluding donors who belong to established risk groups, 3) avoiding non-essential use of blood and blood products, 4) and preparing and using blood and blood products in such a way as to reduce the risk of transmitting AIDS. The present recommendations are made in the absence of a specific, reliable laboratory test for AIDS. Should such a test become available, these recommendations will need to be reviewed.

a. Donor education and selection. Some countries have recommended that persons with AIDS and members of populations with an increased incidence of AIDS voluntarily refrain from donating blood or plasma. Good communication with the donor population is essential to achieve voluntary self-exclusion by risk groups; this requires continuous effort by blood and plasma-collecting organizations. Such self-exclusion is likely to be more effective with volunteer (unpaid) donors. A totally voluntary blood-donor system was recommended in 1975 by WHO (WHA28.72). Good communication also includes spreading the message that no one risks acquiring AIDS by donating blood or plasma under conditions where sterile collection equipment are used.

Donors selected because they have high-titer antibodies to hepatitis B or CMV may be more likely to be members of AIDS risk groups in some countries. This possibility should be considered in the preparation and use of blood products from such individuals. In addition, in situations where human blood or blood components are used to produce hyper-immune materials, precautions must be taken to ensure the safety of the immunized donor.

b. Donor screening using non-specific test to recognize high risk groups. Even in the absence of a specific screening test, laboratory procedures may theoretically help to identify individuals who are at risk of, or likely to transmit AIDS and who should not be accepted as donors. Such tests, which have been proposed by several investigators would tend to identify phenomena associated with particular risk groups but not necessarily directly related to AIDS. Since such tests are not direct measures of AIDS or of susceptibility to AIDS, a certain number of individuals who are not at risk of transmitting AIDS would be excluded from donating blood. This number may vary considerably in different parts of the world, depending upon the characteristics of the risk groups.

Thus, the specificity and sensitivity of any such test(s) for this purpose must be evaluated in the environment in which it is to be applied, taking into consideration potential effectiveness of the test as well as the impact on the blood supply and the potential alienation of donors.

- c. Recordkeeping. Appropriate records are required in blood and plasma donation centres in order to facilitate epidemiologic studies correlating donor and recipient data.
- d. Sample collection. The development of selected serum repositories in blood banks is required for prospective studies.
- e. Plasma processing. Current evidence suggests that immunoglobulin and albumin prepared by generally accepted methods have not been implicated in AIDS and are considered safe. Coagulation factor concentrates, however, have been implicated in cases of AIDS. Although additional inactivation methods have recently been developed, it will not be possible to fully establish their effectiveness until the agent of AIDS is discovered.

There are two approaches to minimizing the risk associated with processed plasma fractions: 1) reduce the number of donors contributing to the products a patient receives and 2) employ process technology aimed at reducing contamination risks. Plasma fractions may be produced from single donor material or from pools obtained from up to 20,000 donors. Since small-pool products expose patients to smaller numbers of donors than large-pool concentrates, individual patients regularly treated with small-pool products have a lower theoretical risk of exposure.

Another approach to reducing the risk of AIDS from plasma fractions is to use specified donor material for a given recipient. An extension of that concept is to use a specified batch of material from a pool of a given size, thus reducing the number of donor exposures by the patient. Use of the specified donor-recipient approach for persons with newly diagnosed hemophilia requiring only infrequent therapy should be explored.

- f. Human hepatitis B virus vaccine. Requirements of hepatitis B vaccines, including aspects of safety, have been formulated and are being reviewed by WHO for separate publication (WHO/BS/83.1391 Rev. 2). Preparations meeting these requirements are considered safe.

VI. CONCLUSIONS AND RECOMMENDATIONS

AIDS is an important health problem in many countries of the world and has international implications. The number of cases reported is steadily increasing in industrialized countries. It is associated with homosexual men with multiple partners, needle sharing among abusers of intravenous drugs, use of pooled plasma products by persons with hemophilia, and blood transfusions.

AIDS has only recently been recognized in tropical countries, and little is known about risk factors or transmission in these areas. AIDS is not known to spread through non-intimate social contact.

In the absence of a specific diagnostic test for AIDS, a clinical case definition has served well for surveillance purposes for the past few years. Using this basic definition, surveillance should be initiated throughout the world to monitor trends and to detect the first occurrence of cases in populations not now known to have AIDS.

Collaborative research between and within countries is needed to broaden the understanding of AIDS and to accelerate the development of control efforts. Several areas deserve emphasis:

- Laboratory research on the etiology of AIDS could be expedited by sharing of scientific information, reagents, specimens, and putative agents; and collaborating on transmission experiments in animals, including nonhuman primates.

- Epidemiological research could benefit greatly from collaborative studies in geographical areas where AIDS has been more recently recognized and where risk factors are poorly understood, studies on the relationship of endemic Kaposi's sarcoma to AIDS, and studies on the use of nonspecific laboratory tests, in expectation of specific tests, to determine their effectiveness in excluding high-risk persons as well as the impact of such tests on the supply of blood.
- Clinical research could be assisted by studies, if possible, internationally coordinated on therapy for both the immunodeficiency condition itself and the various opportunistic infections to reduce the high case-fatality rate, by studies on the disease spectrum of AIDS, especially in tropical countries; and by studies on the relationship of AIDS and other immunodeficiencies to tuberculosis, leprosy, sexually transmitted diseases, and malnutrition.

The occurrence of AIDS places severe burdens on medical staff and facilities, whether in industrialized or non-industrialized communities. Referral to centralized facilities for the diagnosis and care of patients with AIDS is encouraged for areas with limited medical and laboratory facilities and in areas where AIDS is rare. In such areas, physicians and other health-care personnel should be informed regarding the clinical and laboratory information necessary for diagnosis and management, precautions for personnel caring for patients or handling laboratory specimens, and social and behavioural concerns associated with the syndrome.

Sufficient information is available at the present time to permit health authorities to make recommendations which may decrease the incidence of AIDS among certain risk groups. However, the impact of these measures will be initially difficult to evaluate since the average period between exposure and diagnosis of AIDS may exceed 2 years. Measures which may be instituted now include:

- Training medical and technical personnel to use only adequately sterilized injection equipment for medical purposes.
- Persuading individuals with AIDS and persons in groups with an increased incidence of AIDS to voluntarily refrain from donating blood and plasma. Blood and plasma collecting organizations should provide relevant information about AIDS to promote and encourage this voluntary self-exclusion policy.
- Providing information to homosexual men to lower the risk of contracting AIDS in this group.
- Informing persons with hemophilia and their physicians of the potential health hazards of factor VIII or IX products, including the risks related to AIDS.
- Considering the use of autotransfusion using frozen or conventionally stored blood for suitable patients.

Because of WHO's special position of trust, it can provide a unique resource in developing an understanding of AIDS and in planning strategies for eventual control. The Work Group recommends that the WHO:

1. Encourage member countries to adopt the surveillance case definition described in this document for epidemiologic use in all industrialized countries. An adaptation of the AIDS case definition may be necessary for surveillance in countries without extensive laboratory or other specialized facilities, but to assure consistency in case definition and allow assistance where required, WHO should be notified by all countries proposing to use any modified case definition. Consistent use of a suitable definition is essential for comparing data from different countries.
2. Encourage and support collaborative research on AIDS between countries.

3. Publicize widely the safety precautions recommended for personnel taking care of patients with AIDS or handling laboratory specimens.
4. Regularly review specifications for blood and blood products and recommend modifications where appropriate in light of additional information on AIDS transmission.
5. Request the recently designated WHO Centre for information exchange in Europe to coordinate the exchange of information between regions of the world, particularly between developing and industrialized countries of the world. AIDS surveillance information should be made available on a regular basis through WHO publications.

APPENDIX 1

CDC Surveillance Definition of AIDS

- I. Diseases at least moderately predictive of cellular immunodeficiency in the United States.
 - A. Malignancies
 1. Kaposi's sarcoma in persons less than 60 years of age (histopathology).
 2. Lymphoma limited to the brain (histopathology).
 - B. Infections
 1. Protozoal and helminthic infections
 - a. Pneumocystis carinii pneumonia (on histology or on microscopy of a "touch" preparation or bronchial washings).
 - b. Toxoplasmosis, causing pneumonia or CNS infection (on histology or microscopy of a "touch" preparation).
 - c. Cryptosporidiosis, intestinal, causing diarrhea for over one month (on histology or stool microscopy).
 - d. Strongyloidosis, causing pneumonia, CNS infection, or disseminated infection (on histology).
 2. Fungal infections
 - a. Candidiasis, causing esophagitis (on histology, microscopy of a "wet" preparation from the esophagus, or endoscopic findings of which plaques on an erythematous mucosal base).
 - b. Cryptococcosis, causing pulmonary, CNS, or disseminated infection (on culture, antigen detection, histology, or India ink preparation of CSF).
 3. Bacterial infection
 - a. "Atypical" mycobacteriosis (species other than tuberculosis or lepra), causing disseminated infection (on culture).
 4. Viral infection
 - a. Cytomegalovirus, causing pulmonary, gastrointestinal tract, or CNS infection (histology).
 - b. Herpes simplex virus, causing chronic mucocutaneous infection with ulcers persisting more than one month or pulmonary, gastrointestinal tract, or disseminated infection (on culture, histology, or cytology).
 - c. Progressive multifocal leukoencephalopathy (presumed to be caused by papovavirus) (on histology).
- II. Exclusion criteria
 - A. History of recent immunosuppressive therapy before the onset of illness, or
 - B. Presence of another pre-existing illness associated with immunosuppression (e.g., congenital immunodeficiency, lymphoreticular malignancy, severe protein-calorie malnutrition).

APPENDIX 2

Precautions for Health-Care Workers and Allied Professionals

A. Clinical Staff

1. Extraordinary care must be taken to avoid accidental wounds from sharp instruments contaminated with potentially infectious material and to avoid contact of open skin lesions with material from AIDS patients.
2. Gloves should be worn when handling blood specimens, blood-soiled items, body fluids, excretions, and secretions, as well as surfaces, materials, and objects exposed to them.
3. Gowns should be worn when clothing may be soiled with body fluids, blood, secretions, or excretions.
4. Hands should be washed after removing gowns and gloves and before leaving the rooms of known or suspected AIDS patients. Hands should also be washed thoroughly and immediately if they become contaminated with blood.
5. Blood and other specimens should be labelled prominently with a special warning, such as "Blood Precautions" or "AIDS Precautions." If the outside of the specimen container is visibly contaminated with blood, it should be cleaned with a disinfectant (such as a 1:10 dilution of 5.25% sodium hypochlorite household bleach with water). All blood specimens should be placed in a second container, such as an impervious bag, for transport. The container or bag should be examined carefully for leaks or cracks.
6. Blood spills should be cleaned up promptly with a disinfectant solution, such as sodium hypochlorite (see above).
7. Articles soiled with blood should be placed in an impervious bag prominently labelled "AIDS Precautions" or "Blood Precautions" before being sent for reprocessing or disposal. Alternatively, such contaminated items may be placed in plastic bags of a particular colour designated solely for disposal of infectious wastes by the hospital. Disposable items should be incinerated or disposed of in accord with the hospital's policies for disposal of infectious wastes. Reusable items should be reprocessed in accord with hospital policies for hepatitis B virus-contaminated items. Lensed instruments should be sterilized after use on AIDS patients.
8. Needles should not be bent after use, but should be promptly placed in a puncture-resistant container used solely for such disposal. Needles should not be reinserted into their original sheaths before being discarded into the container, since this is a common cause of needle injury.
9. Disposable syringes and needles are preferred. Only needle-locking syringes or one-piece needle-syringe units should be used to aspirate fluids from patients, so that collected fluid can be safely discharged through the needle, if desired. If reusable syringes are employed, they should be decontaminated before reprocessing.
10. A private room is indicated for patients who are too ill to use good hygiene, such as those with profuse diarrhea, fecal incontinence, or altered behaviour secondary to central nervous system infections.

Precautions appropriate for particular infections that concurrently occur in AIDS patients should be added to the above, if needed.


B. Laboratory Staff

1. Mechanical pipetting devices should be used for the manipulation of all liquids in the laboratory. Mouth pipetting should not be allowed.
 2. Needles and syringes should be handled as stipulated in Section A (above).
 3. Laboratory coats, gowns, or uniforms should be worn while working with potentially infectious materials and should be discarded appropriately before leaving the laboratory.
 4. Gloves should be worn to avoid skin contact with blood, specimens containing blood, blood-soiled items, body fluids, excretions, and secretions, as well as surfaces, materials, and objects exposed to them.
 5. All procedures and manipulations of potentially infectious material should be performed carefully to minimize the creation of droplets and aerosols.
 6. Biological safety cabinets (Class I or II) and other primary containment devices (e.g., centrifuge safety cups) are advised whenever procedures are conducted that have a high potential for creating aerosols or infectious droplets. These include centrifuging, blending, sonicating, vigorous mixing, and harvesting infected tissues from animals or embryonated eggs. Fluorescent activated cell sorters generate droplets that could potentially result in infectious aerosols. Translucent plastic shielding between the droplet-collecting area and the equipment operator should be used to reduce the presently uncertain magnitude of this risk. Primary containment devices are also used in handling materials that might contain concentrated infectious agents or organisms in greater quantities than expected in clinical specimens.
 7. Laboratory work surfaces should be decontaminated with a disinfectant, such as sodium hypochlorite solution (see A5 above), following any spill of potentially infectious material and at the completion of work activities.
 8. All potentially contaminated materials used in laboratory tests should be decontaminated, preferably by autoclaving, before disposal or reprocessing.
 9. All personnel should wash their hands following completion of laboratory activities, and removal of protective clothing, and before leaving the laboratory.
- C. Persons handling experimental animals inoculated with materials from individuals with known or suspected AIDS
1. Laboratory coats, gowns, or uniforms should be worn by personnel entering rooms housing inoculated animals. Certain nonhuman primates, such as chimpanzees, are prone to throw excreta and to spit at attendants; personnel attending inoculated animals should wear molded surgical masks and goggles or other equipment sufficient to prevent potentially infective droplets from reaching the mucosal surfaces of their mouths, nares, and eyes. In addition, when handled, other animals may disturb excreta in their bedding. Therefore, the above precautions should be taken when handling them.
 2. Personnel should wear gloves for all activities involving direct contact with experimental animals and their bedding and cages. Such manipulations should be performed carefully to minimize the creation of aerosols and droplets.
 3. Necropsy of experimental animals should be conducted by personnel wearing gowns and gloves. If procedures generating aerosols are performed, masks and goggles should be worn.

4. Extraordinary care must be taken to avoid accidental sticks or cuts with sharp instruments contaminated with body fluids or tissues of experimental animals inoculated with material from AIDS patients.
 5. Animal cages should be decontaminated, preferably by autoclaving, before they are cleaned and washed.
 6. Only needle-locking syringes or one-piece needle-syringe units should be used to inject potentially infectious fluids into experimental animals.
- D. Dental-care personnel
1. Personnel should wear gloves, masks, and protective eyewear when performing dental or oral surgical procedures.
 2. Instruments used in the mouths of patients should be sterilized after use.
- E. Persons performing necropsies or providing morticians' services
1. As part of immediate postmortem care, deceased persons should be identified as belonging to one of the above three groups, and that identification should remain with the body.
 2. The procedures followed before, during, and after the postmortem examination are similar to those for hepatitis B. All personnel involved in performing an autopsy should wear double gloves, masks, protective eyewear, gowns, waterproof aprons, and waterproof shoe coverings. Instruments and surfaces contaminated during the postmortem examination should be handled as potentially infective items.
 3. Morticians should evaluate specific procedures used in providing mortuary care and take appropriate precautions to prevent the parenteral or mucous-membrane exposure of personnel to body fluids.

Fig.1 CASES* OF AIDS, BY YEAR OF DIAGNOSIS,
UNITED STATES, 1978-1983**

N=3,000



* 9 OTHER CASES WITH DATE OF DIAGNOSIS UNKNOWN OR BEFORE 1978

** AS OF DECEMBER 19, 1983

Table 1

AIDS Cases in the United States, as reported by CDC
by December 5, 1983, by Patient Characteristic and Sex

<u>Patient Risk Characteristics*</u>	<u>MALES</u>		<u>FEMALES</u>		<u>TOTAL</u>	
	<u>Cases</u>	<u>Percent of Males</u>	<u>Cases</u>	<u>Percent of Females</u>	<u>Cases</u>	<u>Percent of Total</u>
Homosexual or Bisexual	2052	76.6	0	0.0	2052	71.5
Intravenous (IV) Drug Abuser	387	14.5	103	54.5	490	17.1
Other	<u>240</u>	<u>9.0</u>	<u>86</u>	<u>45.5</u>	<u>326</u>	<u>11.4</u>
Total	2679	100.0	189	100.0	2868	100.0

* Patient characteristics listed are ordered hierarchically; cases with multiple characteristics are tabulated only in the group listed first.

Table 2

AIDS cases per million population,* by standard metropolitan statistical area (SMSA) of residence, reported from June 1, 1981 to December 5, 1983, United States

SMSA of Residence	Cases	Percentage of total	Cases per million population
New York, NY	1208	42.1	132.5
San Francisco, CA	344	12.0	105.8
Miami, FL	123	4.3	75.7
Newark, NJ	78	2.7	39.7
Los Angeles, CA	227	7.9	30.4
Elsewhere	888	31.0	4.4
Total United States	2868	100.0	12.7

* From the 1980 Census

Table 3

Cases of AIDS reported to the European Regional Office of WHO
as of October 20, 1983

Country	Year of Diagnosis						Total
	-79	1979	1980	1981	1982	1983	
Austria						7	7
Belgium			2	4	8	24	38
Czechoslovakia					1	1	2
Denmark			1	2	4	6	13
Finland						2	2
France	6	1	5	5	30	47	94
Germany, Fed. Republic of	1	1			7	33	42
Ireland						2	2
Italy	1				2		3
Netherlands					3	9	12
Norway						2	2
Spain				1	1	4	6
Sweden					1	3	4
Switzerland			2	3	5	7	17
United Kingdom				2	5	17	24
Total	8	2	10	17	67	164	268*

* German Democratic Republic, Greece, Hungary, Luxembourg, Poland, USSR, and Yugoslavia reported no cases. No information was received from other countries.